Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28026146 | 0.89 | RRM1 (0.53) | NOD1EPHX1RRM1DPP7GNAI3 | |
| SCHEMBL28847291 | 0.88 | NOD1 (0.49) | NOD1EPHX1RRM1DPP7GNAI3 | |
| SCHEMBL2251083 | 0.86 | NOD1 (0.51) | NOD1 | |
| SCHEMBL28043982 | 0.86 | SIRT6 (0.57) | NOD1EPHX1RRM1DPP7GNAI3 | |
| SCHEMBL2244646 | 0.86 | NOD1 (0.51) | NOD1 | |
| SCHEMBL30812451 | 0.86 | NOD1 (0.51) | NOD1 | |
| SCHEMBL28346802 | 0.86 | SIRT6 (0.57) | NOD1EPHX1RRM1DPP7GNAI3 | |
| SCHEMBL7622596 | 0.86 | SIRT6 (0.57) | NOD1EPHX1RRM1DPP7GNAI3 | |
| SCHEMBL28962963 | 0.86 | SIRT6 (0.49) | NOD1EPHX1RRM1DPP7GNAI3 | |
| SCHEMBL17541390 | 0.86 | SIRT6 (0.49) | NOD1EPHX1RRM1DPP7GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357358-A1 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | BLUEBIRD VENTURES I, L.P. | 2023-11-09 | — | — | US | disclosed |
| US-11746139-B2 | IL-7Rαγc binding compounds | MEDIKINE, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746139-B2 | IL-7Rαγc binding compounds | IL2RA, IL23R, IL6ST | NOD1 227/4885EPHX1 4207/4885RRM1 3779/4885 |
| US-20230357358-A1 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | IL2RA, IL2, IL6ST | NOD1 282/4885EPHX1 4131/4885RRM1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.